Luoda is developing a unique oral liquid combination product to improve compliance and effectiveness.
Congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation) in dogs.
|Development Status:||Clinical Development Ongoing|
|Licence Status:||First stage funding obtained|
|Commercialisation Date:||Estimated 2019|